Associate professor of medicine, Vanderbilt University

Dr. Mayer research endeavors have been focused on 1) the identification of targetable pathways in breast cancer, 2) ErbB signaling and endocrine therapy resistance in estrogen receptor positive (ER+) breast cancers, 3) PI3K signaling and endocrine therapy resistance in ER+ breast cancers, 4) chemotherapy resistance in triple negative breast cancers, and 5) biomarker prediction of treatment response in human breast cancers.
Identification of targetable pathways in breast cancer. To enhance understanding of breast cancer biology and to elucidate molecular determinants of clinical efficacy, Dr. Mayer obtained a Vanderbilt Physician Scientist Development (VPSD) Award. The specific aims of this grant were to identify relevant tumor antigens by multidimensional liquid chromatography (LC) and tandem mass spectrometry (MS) using antibodies raised against specific peptide motifs recognized by circulating IgGs in breast cancer patients sera and to determine if these tumor antigens could be detected by immunohistochemistry in all different subsets of primary breast tumors.

Experience

  • –present
    Associate professor of medicine, Vanderbilt University